Drug Profile
Research programme: anti-cancer immunomodulators - Yuhan Corporation
Alternative Names: YH14810Latest Information Update: 13 Jan 2016
Price :
$50
*
At a glance
- Originator Yuhan
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Jan 2016 Discontinued - Preclinical for Cancer in South Korea (Parenteral)
- 16 Dec 2014 Preclinical development is ongoing in South Korea
- 20 Aug 2012 Preclinical trials in Cancer in South Korea (Parenteral)